Safety of the Co-administration of Three Drugs for Trachoma and Lymphatic Filariasis Elimination

Completed 3000 enrolled Centre d'Appui à la lutte contre la Maladie International Trachoma Initiative · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether the triple co administration of albendazole, ivermectin and azithromycine is as safe as the current treatment scheme that consists to treat with albendazole plus ivermectin together and a week later to treat with azithromycin in areas co endemic for lymphatic filariasis and trachoma.

Timeline

Start: 2010-02
Primary completion: 2010-02
Completion: 2010-02

Outcome

Results reported · no primary-endpoint met/missed verdict (typical of a dose-finding / safety study)

paper inability to calculate a meaningful overall estimate of the difference in adverse event rates between the regimens. PMID 23675549 ↗

Publications

Coulibaly YI, Dicko I, Keita M, Keita MM, Doumbia M, Daou A, Haidara FC, Sankare MH, Horton J, Whately-Smith C, Sow SO. A cluster randomized study of the safety of integrated treatment of trachoma and lymphatic filariasis in children and adults in Sikasso, Mali. PLoS Negl Trop Dis. 2013 May 9;7(5):e2221. doi: 10.1371/journal.pntd.0002221. Print 2013.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Albendazole	Small molecule	400 mg	—
Subject	Azithromycin	Small molecule	—	—
Subject	Ivermectin	Small molecule	—	—